FTC Testimonial Guide Moves Past "Results Not Typical," Enters Blog Era
This article was originally published in The Pink Sheet Daily
Federal Trade Commission guidelines previously allowed use of the disclaimer phrase "results not typical" - often used in weight-loss product advertising - as a safe harbor from liability, but FTC now expects clear disclosure of what the typical results actually are.
You may also be interested in...
Celgene will get exclusive use of Quanticel's single-cell genomic analysis to tweak its clinical pipeline, and it also has exclusive options to acquire the venture-backed start-up.
With an unrestricted label and once-daily dosing, rivaroxaban will do battle with Boehringer-Ingelheim's dabigatran, which is dosed twice a day but can claim superior efficacy to warfarin in the atrial fibrillation population.
One Trial Plus Supportive Evidence Is Enough For Hospital-, Ventilator-Acquired Pneumonia Indication, Panel Says
Anti-Infective Drugs Advisory Committee members viewed one-trial as practical means of gaining efficacy data.